Organizational Impact of Immunotherapies in Advanced Cancers in France

Overview

Journal JCO Glob Oncol

Specialty Oncology

Date 2023 Aug 18

PMID 37595168

Authors

Valentine Grumberg

Christos Chouaid

Anne-Francoise Gaudin

Christophe Le Tourneau

Aurelien Marabelle

Isabelle Bongiovanni-Delaroziere

Francois-Emery Cotte

Isabelle Borget

Affiliations

Soon will be listed here.

Abstract

Purpose: In 2020, the French National Authority for Health () published a methodologic guide called organizational impact (OI) cartography to define and structure assessment of the OI of health technologies. As immunotherapies are associated with extended survival and improved quality of life in advanced cancer, we aimed to identify OIs that immunotherapies had on health care systems and professionals. To our knowledge, we suggest the first implementation for OI assessment on the basis of the cartography.

Methods: A literature review was conducted, and interviews with health care professionals (HCPs) were performed to identify OIs of immunotherapies. They were asked if immunotherapies had OIs classified into three macrocriteria, namely, impact on the care process (six criteria), impact on capacities and skills required (six criteria), and impact on society (four criteria). If an OI was mentioned for a criterion, information on its impact (minor/moderate/major) and its timing was collected. We considered that an OI existed when 75% of HCPs mentioned an impact for a given criterion.

Results: Overall, 27 HCPs were interviewed. For 12 of 16 criteria, most HCPs mentioned an impact, whereas the literature identified impacts for 11 criteria. Four criteria (skills and transfer between HCPs, scheduling capabilities, and social relationship) had consensus among HCPs and a high impact; two criteria (rhythm or care duration, working/living conditions) showed consensus but a moderate impact; two criteria (funding and scheduling capabilities cross-structure) had a high impact but no consensus. For eight criteria (as environment or inequity), there was no consensus and moderate impact.

Conclusion: The introduction of immunotherapies for advanced cancer has had an important OI in France, regarding capacities and skills. Further research using qualitative analysis of interviews will provide more information regarding OI.

References

Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M . Long-term immune-related adverse events after discontinuation of immunotherapy. Immunotherapy. 2021; 13(9):735-740. DOI: 10.2217/imt-2020-0320. View

Pascal C, Mathy C, Bongiovanni I, Konishi M . Integrating organizational impacts into health technology assessment (HTA): an analysis of the content and use of existing evaluation frameworks. Int J Technol Assess Health Care. 2022; 38(1):e80. DOI: 10.1017/S0266462322003221. View

Castel H, Joly F . [Immunotherapies of cancer: Is there any impact on patient cognitive functions?]. Med Sci (Paris). 2020; 36(8-9):695-699. DOI: 10.1051/medsci/2020139. View

Cairns L, Aspeslagh S, Anichini A, Kyte J, Blank C, Ascierto P . Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation. Ecancermedicalscience. 2016; 10:691. PMC: 5130327. DOI: 10.3332/ecancer.2016.691. View

Scherpereel A, Durand-Zaleski I, Cotte F, Fernandes J, Debieuvre D, Blein C . Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. BMC Cancer. 2018; 18(1):1013. PMC: 6196460. DOI: 10.1186/s12885-018-4958-5. View

Denis H, Davoine C, Bermudez E, Grosjean G, Schwager M, Ifrah N . [Specific immunotherapies in the treatment of cancers]. Bull Cancer. 2019; 106(1):37-47. DOI: 10.1016/j.bulcan.2018.12.007. View

Kaufman H, Atkins M, Subedi P, Wu J, Chambers J, Mattingly 2nd T . The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019; 7(1):129. PMC: 6525438. DOI: 10.1186/s40425-019-0594-0. View

Legoupil C, Debieuvre D, Marabelle A, Michiels S, Kapso R, Besse B . A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. ERJ Open Res. 2020; 6(2). PMC: 7167209. DOI: 10.1183/23120541.00174-2019. View

Ceyrac T, Corny J, Raybaut C, Degrassat-Theas A, Paubel P . [Market access agreements: Definition and features. Could MAA be defined as a solution for immunotherapy funding by French health system?]. Ann Pharm Fr. 2018; 76(4):265-272. DOI: 10.1016/j.pharma.2018.01.005. View

10.

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F . Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2015; 27(4):559-74. DOI: 10.1093/annonc/mdv623. View

11.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V . Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(5):706-720. DOI: 10.1093/annonc/mdz056. View

12.

Cotte F, Voillot P, Bennett B, Falissard B, Tzourio C, Foulquie P . Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study. J Med Internet Res. 2020; 22(9):e19694. PMC: 7519426. DOI: 10.2196/19694. View

13.

Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K . Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol. 2020; 17(11):707-715. DOI: 10.1038/s41571-020-0399-6. View

14.

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

15.

Patrinely Jr J, Johnson R, Lawless A, Bhave P, Sawyers A, Dimitrova M . Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021; 7(5):744-748. PMC: 7995124. DOI: 10.1001/jamaoncol.2021.0051. View

16.

Danson S, Hook J, Marshall H, Smith A, Bell S, Rodwell S . Are we over-treating with checkpoint inhibitors?. Br J Cancer. 2019; 121(8):629-630. PMC: 6889152. DOI: 10.1038/s41416-019-0570-y. View

17.

Gobbini E, Toffart A, Boisserie Lacroix L, Pinsolle J, Schoutteten L, Federspiel I . Immune checkpoint inhibitors and hospitalization at home in France. Bull Cancer. 2021; 109(1):89-97. DOI: 10.1016/j.bulcan.2021.09.012. View

18.

Domnariu P, Noel N, Hardy-Leger I, Michot J, Lambotte O . Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study. Eur J Cancer. 2021; 148:211-214. DOI: 10.1016/j.ejca.2021.02.018. View

19.

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View

20.

Kourie H, Awada G, Awada A . The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. Immunotherapy. 2017; 9(8):647-657. DOI: 10.2217/imt-2017-0029. View